# EDGAR Filing Document

**Accession Number:** 0001601830
**File Stem:** 0001601830-26-000054
**Filing Date:** 2026-3
**Character Count:** 11292
**Document Hash:** cacb7589fbe0bc74dc9b5489869c0d62
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001601830-26-000054.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001601830-26-000054

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260325

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RECURSION PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001601830
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464099738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40323
- **FILM NUMBER:** 26793052

**BUSINESS ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
- **BUSINESS PHONE:** (385) 269-0203

**MAIL ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Recursion Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20140305

?xml version='1.0' encoding='ASCII'? rxrx-20260325

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 25, 2026

**RECURSION PHARMACEUTICALS, INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Delaware**  | **001-40323** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **46-4099738** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

**41 S Rio Grande Street**

**Salt Lake City, UT 84101**

(Address of principal executive offices) (Zip code)

**(385) 269 - 0203**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, par value $0.00001 per share | RXRX | Nasdaq Global Select Market  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

------

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 25, 2026, Recursion Pharmaceuticals, Inc. (the "Company") announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026, as David Mauro, M.D., Ph.D. transitions out of the role. In connection with his departure, Dr. Mauro will continue to serve the Company in an advisory capacity for a transitional period until May 29, 2026.

**Item 7.01. Regulation FD Disclosure.**

On March 25, 2026, the Company issued a press release announcing the CMO transition described in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | <u>[Press Release of Recursion Pharmaceuticals, Inc. dated March 25, 2026.](exhibit991-pr.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on March 25, 2026.

---

| | |
|:---|:---|
| RECURSION PHARMACEUTICALS, INC. | RECURSION PHARMACEUTICALS, INC. |
| By: | /s/ Nathan Hatfield |
|  | Nathan Hatfield |
|  | Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer**

SALT LAKE CITY, Utah, March 25, 2026 at 8:00 am ET (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role.

As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with particular expertise in oncology, as well as experience in clinical practice and as an FDA reviewer.

"We are very excited to welcome Dr. Goodman to Recursion. Vicki's depth of clinical development experience, sound judgment, and the clarity with which she approaches advancing programs through critical regulatory and clinical inflection points are the leadership skills that will help us advance our clinical pipeline," said Najat Khan, Ph.D., CEO and President of Recursion. "This combination of experience, especially at the later stages of clinical development, will be invaluable as we translate scientific insight into disciplined, high-quality programs and deliver differentiated medicines for patients."

"Recursion stands apart in the industry through its ambitious integration of scientific and technological rigor to reimagine how medicines are discovered and developed through the power of AI," said Dr. Goodman. "I'm thrilled to join the company at such an important moment. I look forward to working with Najat, the leadership team, and the broader organization to advance the pipeline, support smart and disciplined development decisions, and help bring impactful new therapies to patients."

Dr. Goodman is a seasoned physician executive with more than two decades of experience in oncology drug development and medical leadership. Most recently, she served as Chief Medical Officer of Mural Oncology, where she built and led the development organization and advanced a portfolio of novel cytokine assets. Previously, she was Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer at Exelixis, where she oversaw early- and late-stage clinical development, regulatory affairs, pharmacovigilance, and biometrics across a multi-asset pipeline.

She has held senior oncology leadership roles at Merck, where she served as Vice President of Clinical Research and Therapeutic Area Head of Late-Stage Oncology, overseeing key elements of the company's late-stage portfolio, including KEYTRUDA® (pembrolizumab), across a broad range of tumor types. Prior to that, at Bristol Myers Squibb, she was a member of the Oncology Senior Leadership Team and led cross-functional development for OPDIVO® (nivolumab) and YERVOY® (ipilimumab) in melanoma and genitourinary cancers.

Earlier in her career at GlaxoSmithKline, Dr. Goodman led development of dabrafenib from early clinical expansion through regulatory approval, and contributed to the advancement of multiple oncology assets entering clinical development.

------

Before she began her career as a Medical Officer in the U.S. Food and Drug Administration, Dr. Goodman received her M.D. from Albert Einstein College of Medicine and completed her clinical training in internal medicine and hematology/oncology at the University of Michigan.

Concurrently, Recursion's current CMO, David Mauro, M.D., Ph.D. will be transitioning from his role after approximately three years.

"Recursion has been a remarkable place to serve, and I'm proud of what we've built together over the past several years," said Dr. Mauro. "I'm especially grateful to my colleagues across clinical development and the broader organization for their collaboration and commitment to patients. I believe Recursion is uniquely positioned at the intersection of technology and drug development, and I look forward to watching the continued progression of the pipeline to potential treatments for patients in the years ahead."

"On behalf of everyone at Recursion, I want to thank Dr. Mauro for his leadership, partnership, and many contributions to our clinical organization and pipeline," said Najat Khan, Ph.D., CEO and President of Recursion. "Since joining Recursion, David has helped strengthen our medical organization, guided the advancement of our clinical portfolio, and supported important milestones across our programs, including the continued progression of REC-4881. We are grateful for his dedication to our mission."

Recursion's platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at <u>www.recursion.com</u>, or connect on <u>X</u> and <u>LinkedIn</u>.

Investor Contact

<u>investor@recursion.com</u>

Media Contact

<u>media@recursion.com</u>

<br>